Table 4 Disease-free and overall survivals in the total entire population and subgroups

From: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

   

Disease-free survival

Overall survival

 

No.

Median (months)

Median (months)

 

GEM

Surgery-only

GEM

Surgery-only

HR (95% CI)

P -value

GEM

Surgery-only

HR (95% CI)

P -value

All patients

58

60

11.4

5.0

0.60 (0.40–0.89)

0.01

22.3

18.4

0.77 (0.51–1.14)

0.19

R0

47

52

11.4

5.1

0.58 (0.37–0.91)

0.02

26.8

19.1

0.70 (0.45–1.09)

0.11

R1

11

8

9.5

3.4

0.39 (0.15–1.06)

0.05

18.3

17.6

1.05 (0.41–2.72)

0.92

N0

19

18

—

9.0

0.38 (0.16–0.86)

0.02

32.0

28.4

0.63 (0.29–1.37)

0.24

N1

39

42

8.6

4.5

0.73 (0.46–1.16)

0.19

17.1

17.3

0.84 (0.53–1.34)

0.84

Stage I–II

13

14

—

10.0

0.27 (0.08–0.85)

0.02

67.8

—

0.42 (0.15–1.22)

0.10

Stage III–IV

45

46

8.9

4.6

0.68 (0.44–1.05)

0.08

18.3

16.3

0.82 (0.53–1.26)

0.36

  1. Abbreviations: CI=confidence interval; GEM=gemcitabine; HR=hazard ratio.
Back to article page